UK experts are warning that access to new weight-loss drugs could depend more on wealth than medical need. Strict NHS criteria mean only a limited number of patients will receive Mounjaro, while many others must pay privately. Researchers say this risks worsening existing health inequalities, especially for groups whose conditions are often missed or under-diagnosed. They are calling for fairer, more inclusive access before gaps in care widen further.
View the full article